MorphoSys AG (MOR) PT Set at €68.00 by Berenberg Bank

Berenberg Bank set a €68.00 ($80.00) target price on MorphoSys AG (ETR:MOR) in a report released on Wednesday. The firm currently has a buy rating on the stock.

A number of other equities research analysts have also recently commented on the company. Independent Research GmbH set a €77.00 ($90.59) target price on MorphoSys AG and gave the company a buy rating in a report on Monday, May 29th. Commerzbank Ag set a €76.00 ($89.41) target price on MorphoSys AG and gave the company a buy rating in a report on Tuesday, May 30th. J P Morgan Chase & Co reiterated a neutral rating on shares of MorphoSys AG in a report on Monday, July 17th. HSBC Holdings plc set a €59.00 ($69.41) target price on MorphoSys AG and gave the company a neutral rating in a report on Friday, July 14th. Finally, Goldman Sachs Group, Inc. (The) set a €55.00 ($64.71) target price on MorphoSys AG and gave the company a neutral rating in a report on Tuesday, June 6th. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average price target of €69.57 ($81.85).

MorphoSys AG (ETR MOR) opened at 56.922 on Wednesday. MorphoSys AG has a 12 month low of €35.72 and a 12 month high of €70.90. The company’s 50-day moving average price is €61.24 and its 200-day moving average price is €57.85. The stock’s market cap is €1.65 billion.

TRADEMARK VIOLATION NOTICE: “MorphoSys AG (MOR) PT Set at €68.00 by Berenberg Bank” was published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece on another website, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this piece can be viewed at https://stocknewstimes.com/2017/08/20/morphosys-ag-mor-pt-set-at-68-00-by-berenberg-bank.html.

MorphoSys AG Company Profile

MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.

Analyst Recommendations for MorphoSys AG (ETR:MOR)

Receive News & Ratings for MorphoSys AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys AG and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply